Blood Banking (CMV)

Leukocyte-Reduction Is Effective As Screening for Preventing CMV

Published in Blood Weekly, December 11th, 1995

Filtered leukocyte-reduced blood products may become accepted as an effective alternative to seronegative blood for preventing transfusion-transmitted cytomegalovirus (CMV) infection in patients receiving bone marrow transplantation (BMT).

For immunocompromised patients who are CMV seronegative, primary CMV infection transmitted by transfusion is a significant problem, noted Raleigh A. Bowden, Fred Hutchinson Cancer Research Center, Seattle, Washington, and colleagues.

For CMV seronegative BMT patients with CMV negative marrow donors, the transfusion of CMV seronegative blood products now is considered standard care.

Bowden et al....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry